Dynavax Technologies Inc. (DVAX) stock soars during pre-market trading session, given no recent update.

PBYI Stock
PBYI Stock

Dynavax Technologies Inc. (NASDAQ: DVAX) stock gained by 7.57% at the last close while the DVAX stock price surges by 4.06% in the pre-market trading session. Dynavax is a biopharmaceutical firm in the commercial stage that is developing and commercializing new vaccines. HEPLISAV-B, the company’s first commercial medication, is authorized in the United States and the European Union for the prevention of hepatitis B virus infection characterized by all known subtypes in adults aged 18 and up.

>> 7 Top Picks for the Post-Pandemic Economy << 

DVAX stock’ Recent Development

Medigen Vaccine Biologics Corporation and Dynavax Technologies Corporation have announced the availability of the MVC-COV1901 COVID-19 vaccine. This week, around 600,000 people are expected to receive the Medigen vaccine.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


Read More

MVC gained Taiwan Emergency Use Authorization and approval in July to include MVC-COV1901 in Taiwan’s COVID-19 vaccine immunization programme. MVC COVID-19 vaccine is recommended for individuals over the age of 20 and is given in two doses 28 days apart for COVID-19 protection.MVC should produce a monthly safety control report during the stated EUA period, and a vaccination effectiveness report within one year of receiving EUA approval, according to the Advisory Committee.

Official Statements

Chen, Chief Executive Officer at Medigen stated,

Medigen is grateful for the opportunity to assist the Taiwanese people and contribute to the worldwide response to the pandemic. They were grateful to the Taiwan FDA for granting emergency use authorization, and they appreciate the time and effort put in by both the TFDA employees and the experts who attended the potential risks and benefits analysis meeting. It’s encouraging to see a positive outcome from the Medigen team’s tireless efforts.

>> 7 Top Picks for the Post-Pandemic Economy << 

Ryan Spencer, Chief Executive Officer of DVAX said,

They are glad to announce that Medigen’s vaccination is now available to Taiwanese citizens. They’re really thrilled for this first EUA and authorization for COVID-19 vaccines with CpG 1018 adjuvant, which they anticipate will be the start of many. They believe that adjuvanted vaccines can make a substantial contribution to existing vaccination efforts, despite the constraints of current vaccines and the worldwide vaccine deficit.


Please enter your comment!
Please enter your name here